Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Morgello

Showing results (161-170 of 223) with videos related to

Pageof 23
Sort By:
Journal of Neurovirology|May 18, 2019
The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathiesJessica Robinson-Papp, Alexandra Nmashie, Elizabeth Pedowitz, et al.
Neurology|December 16, 2014
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peopleDavid B Clifford, Florin Vaida, Yu-Ting Kao, et al.
The Journal of Antimicrobial Chemotherapy|January 22, 2013
Etravirine in CSF is highly protein boundAnh Nguyen, Steven Rossi, David Croteau, et al.
Viruses|December 23, 2023
Elevated Plasma Protein Carbonyl Concentration Is Associated with More Abnormal White Matter in People with HIVPatricia K Riggs, Albert M Anderson, Bin Tang, et al.
Journal of Neurovirology|January 6, 2016
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort studyEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Archives of Neurology|May 12, 2010
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER StudyRonald J Ellis, Debralee Rosario, David B Clifford, et al.
AIDS (London, England)|September 29, 2012
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriersVirawudh Soontornniyomkij, David J Moore, Ben Gouaux, et al.
American Journal of Epidemiology|June 27, 2014
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIVEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Journal of Neurovirology|February 14, 2022
Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluidDipesh Solanky, Jerel A Fields, Jennifer E Iudicello, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2010
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1David Croteau, Scott Letendre, Brookie M Best, et al.
Pageof 23

Showing results (161-170 of 223) with videos related to

Sort By:
Pageof 23
Journal of Neurovirology|May 18, 2019
The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathiesJessica Robinson-Papp, Alexandra Nmashie, Elizabeth Pedowitz, et al.
Neurology|December 16, 2014
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peopleDavid B Clifford, Florin Vaida, Yu-Ting Kao, et al.
The Journal of Antimicrobial Chemotherapy|January 22, 2013
Etravirine in CSF is highly protein boundAnh Nguyen, Steven Rossi, David Croteau, et al.
Viruses|December 23, 2023
Elevated Plasma Protein Carbonyl Concentration Is Associated with More Abnormal White Matter in People with HIVPatricia K Riggs, Albert M Anderson, Bin Tang, et al.
Journal of Neurovirology|January 6, 2016
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort studyEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Archives of Neurology|May 12, 2010
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER StudyRonald J Ellis, Debralee Rosario, David B Clifford, et al.
AIDS (London, England)|September 29, 2012
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriersVirawudh Soontornniyomkij, David J Moore, Ben Gouaux, et al.
American Journal of Epidemiology|June 27, 2014
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIVEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Journal of Neurovirology|February 14, 2022
Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluidDipesh Solanky, Jerel A Fields, Jennifer E Iudicello, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2010
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1David Croteau, Scott Letendre, Brookie M Best, et al.
Pageof 23